Ultravist 370(iopromide) solution for injections 370 mg/ml. 50 ml. vial №1


The drug is used solely for diagnosis. Ultravist 300 and Ultravist 370 are used to contrast when performing computed tomography (CT), angiography, angiocardiography, digital subtraction angiography (CAA); urography and examination of the body cavities (except myelography, ventriculography, cisternography).



Composition and form of release
Active ingredient: iopromide 0.623 mg / ml (equivalent to 370 mg / ml of iodine). Ultravist 370 is produced in the form of a solution for injection.
Pharmacological properties
It is an iodine-containing radiopaque substance. When injected intravascularly, it makes the blood flow opaque to X-rays, which provides radiographic imaging of the circulatory system of organs.
Ultravist 370 is shown:

  •  for contrast enhancement in computed tomography;
  •  for arteriography, phlebography, including internal arterial digital subtraction angiography;
  •  for intravenous urography;
  •  for the study of body cavities (arthrography, hysterosalpingography), with the exception of the subarachnoid space.

The drug Ultravist 370 is not used:

  •  with increased sensitivity to iodine-containing substances;
  •  with intolerance to excipients;
  •  with severe hyperthyroidism.

Used with caution:

  •  in case of impaired renal function;
  •  with diseases of the kidneys, liver;
  •  with homozygous sickle cell anemia;
  •  with multiple myeloma, other paraproteinemia;
  •  with anuria;
  •  with diabetes mellitus.

Application during pregnancy and lactation
Studies do not indicate a direct or indirect negative impact on the course of pregnancy, embryo development, childbirth, postnatal development. However, sufficiently controlled studies have not been conducted, therefore, during pregnancy, it is necessary to use the drug with extreme caution.
The ability of Joversol to be excreted in breast milk is unknown. But it is known that many injectable contrast agents are excreted unchanged in breast milk (approximately 1% of the administered dose). Although no adverse reactions have been identified, caution should be exercised with intravascular administration to nursing patients. It is recommended to stop feeding for 24 hours.
Method of administration and dosage
Ultravist 370 is used according to the diagrams in the instructions.
Apply the lowest dose that provides adequate visualization.
Overdose can be potentially life-threatening, manifested by cardiovascular and respiratory disorders.
Treatment is symptomatic, hemodialysis is indicated.
Side effects
Immune disorders: manifestations of allergies, incl. anaphylactoid reactions, anaphylactic shock.
Mental disorders: agitation, confusion, anxiety.
Neurological disorders: fainting, vertigo, tremor, headache, delirium, paresthesia, taste disturbances, loss of consciousness, speech impairment, paralysis, drowsiness, aphasia, stupor, dysphasia, hypesthesia, dyskinesia, convulsions, amnesia.
Ophthalmic disorders: blurred vision, allergic conjunctivitis, eye irritation, lacrimation, redness, conjunctival edema, transient blindness.
Otolaryngological disorders: ringing in the ears.
Cardiovascular disorders: tachycardia, heart block, ECG changes, bradycardia, arrhythmia, angina pectoris, atrial fibrillation, cardiac arrest, coronary artery spasm, ventricular fibrillation, cyanosis, palpitations, extrasystole, arterial hypotension, circulatory hypertension, hypotension / hypertension, hypotension phlebitis, vasodilation, vasospasm, shock, thrombosis, hemodynamic collapse.
Respiratory disorders: laryngospasm, edema, airway obstruction, nasal congestion, stridor, shortness of breath, sneezing, cough, sore throat, pulmonary edema, hypoxia, pharyngitis, respiratory arrest, bronchospasm, apnea, asthma, dysphonia.
Gastrointestinal disorders: dry mouth, nausea, sialadenitis, tongue edema, abdominal pain, dysphagia, diarrhea, hypersalivation.
Dermatological disorders: urticaria, rash, erythema, pruritus, Quincke’s edema, pallor, hyperhidrosis, toxic epidermal necrolysis.
Musculoskeletal disorders: muscle cramps.
Urinary disorders: involuntary urination, renal failure, decreased creatinine clearance, incontinence, hematuria, increased urea levels, dysuria, anuria, oliguria.
General: fever, facial edema, pharyngeal edema, chills, tremors, changes at the injection site (pain, hemorrhage, erythema, necrosis), asthenic conditions, feeling unwell, chest pain, hyperthermia.
Storage conditions and periods
Store Ultravist 370 at temperatures up to +30 ° С for no more than three years.